Eton Pharmaceuticals, Inc.
ETONHealthcareNASDAQDrug Manufacturers - Specialty & Generic
Scan Results
Daily timeframeHeadquartered within the healthcare sector, Eton Pharmaceuticals, Inc. focuses on Drug Manufacturers - Specialty & Generic services and products. Eton Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing treatments for rare diseases. Valued at $1.70B, ETON is a small-cap name in its sector. Its commercial rare disease products include Increlex for the treatment of severe primary igf-1 deficiency; Alkindi Sprinkle for adrenal insufficiency; Khindivi for adrenocortical insufficiency; Galzin for Wilson disease; PKU Golike for phenylketonuria; Carglumic Acid for N-acetylglutamate synthase deficiency; Betaine Anhydrous for homocystinuria; and Nitisinone for tyrosinemia type 1.
Market Cap
$1.70B
Beta
0.90
P/E (TTM)
152.17
P/E (Fwd)
23.00
EPS (TTM)
$0.39
EPS (Fwd)
$2.58
ROE
36.0%
ROA
11.9%
Cash
$26.8M
Total Debt
$29.2M
Free CF
$6.6M
52W Change
235.5%
Annual Financials
Cash vs Debt
Where ETON stands vs its 150-day and 200-day moving averages
As of the September 3, 2026 close, ETON finished 95.09% above its 150-day moving average ($31.76) and 122.48% above its 200-day moving average ($27.85). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is ETON overbought or oversold?
At the September 3, 2026 close, ETON's RSI(14) was 78.1, in overbought territory (above 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
Eton Pharmaceuticals, Inc. carries $29.2M in total debt against $26.8M in cash reserves — debt is modestly above the cash position. Managing this leverage effectively will be important for long-term financial stability. Free cash flow comes in at $6.6M, providing flexibility for reinvestment, buybacks, or dividends. Consistent free cash flow generation is often considered a sign of operational health. Return on equity stands at 36.0%, which is exceptionally high for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Return on assets of 11.9% further supports the picture of efficient asset utilization. Revenue has grown from $21.3M (2022) to $80.0M (2025), reflecting a 276% increase over the period.
At over 50x earnings, ETON carries valuation risk — any slowdown in growth expectations could lead to meaningful price adjustments. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for Eton Pharmaceuticals, Inc. and its sector.